AAP
OKUR

Arax Advisory Partners’s OnKure Therapeutics OKUR Stock Holding History

Arax Advisory Partners’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$291 – 2790
2024
Q3 		$291 Hold
17
– – ﹤0.01% 2478
2024
Q2 		$259 Buy
+17
New +$288 ﹤0.01% 2423

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arax Advisory Partners's OKUR Position: Q4 2024 in Review

Arax Advisory Partners sold out of OnKure Therapeutics (OKUR) in Q4 2024, closing a stake of 17 shares — an estimated $291 sold.

Arax Advisory Partners first reported a position in OKUR in Q2 2024 and held it in 2 quarters. The position peaked at $291 in Q3 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q4 2024.

  • Arax Advisory Partners reported no remaining OnKure Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 17 OnKure Therapeutics shares in Q4 2024, an estimated $291.
  • Arax Advisory Partners first reported a position in OnKure Therapeutics in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's OnKure Therapeutics position peaked at $291 in Q3 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.